Q-omics provides the consensus-scored CCL15-CCL14 profile across patient tissues and cancer cell-line models. CCL15-CCL14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCL15-CCL14 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CCL15-CCL14 RNA expression shows 12,307 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, KIRC, and ESCA as cancer lineages where CCL15-CCL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL15-CCL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL15-CCL14 survival associations across molecular data types. CCL15-CCL14 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL15-CCL14 RNA expression–survival associations across cancer types. High CCL15-CCL14 expression shows unfavorable associations in KICH, UCEC and LGG, but favorable associations in KIRP, BLCA and OV. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify KIRP as the clearest survival context for CCL15-CCL14 RNA expression.
This table summarizes CCL15-CCL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCL15-CCL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL15-CCL14 shows lower tumor expression in COAD, KICH, LUSC and LUAD and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher CCL15-CCL14 RNA expression in tumor versus normal tissue (log2 FC = +0.960, t-test p < 0.001).
This table shows molecular features associated with CCL15-CCL14 in patient tissues and cancer cell lines. In patient samples, CCL15-CCL14 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL15-CCL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT.
